Precisely Driving PROTAC Development: Human BCL6/CRBN Molecular Glue Binding Detection Kit
In the field of targeted protein degradation, particularly in the development of molecular glue drugs targeting the critical transcription factor BCL6, how to rapidly and accurately quantify the efficiency of ternary complex formation induced by candidate compounds is a key step in accelerating lead compound discovery and optimization.
- Recent Advances
- Product Information
In the field of targeted protein degradation, particularly in the development of molecular glue drugs targeting the critical transcription factor BCL6, the ability to rapidly and accurately quantify the efficiency of candidate compounds in inducing ternary complex formation is a key step in accelerating lead compound discovery and optimization.
To address this need, we present the Human BCL6/CRBN PROTAC Binding Kit. This kit utilizes advanced homogeneous time-resolved fluorescence (TR-FRET) technology, specifically designed for quantitative detection of molecular glue (e.g., ARV-393)-mediated inducible interactions between the DDB1/CRBN E3 ubiquitin ligase complex and BCL6 target protein, providing a powerful tool for high-throughput screening and mechanistic studies.
I. Core Principle: Direct "Visualization" of Protein Complex Assembly
This kit employs a homogeneous, wash-free detection format, directly reporting ternary complex formation through sensitive TR-FRET signals.
Intelligent Detection Design: The kit provides Eu-labeled donor antibodies and acceptor-labeled receptor antibodies, which specifically recognize different tags on the DDB1/CRBN complex and BCL6 protein, respectively.
Key to Signal Generation: When an effective molecular glue (e.g., ARV-393) is present in the sample, it acts as a "bridge," inducing close spatial proximity between DDB1/CRBN and BCL6, thereby bringing the corresponding donor and receptor antibodies into close proximity.
From Energy Transfer to Specific Signal: When the donor Eu is excited by a specific light source, its energy is efficiently transferred to the nearby acceptor via fluorescence resonance energy transfer (FRET), ultimately generating a long-lived specific fluorescence signal at 665 nm. The intensity of this signal is directly proportional to the amount of ARV-393-mediated ternary complex formation, enabling precise quantification.
II. Why Choose This Kit? Core Advantages at a Glance
| Advantage Dimension | Limitations of Traditional Methods | This Kit's Solution |
|---|---|---|
| Workflow | Multi-step, requires washing (e.g., ELISA, Pull-down), time-consuming and labor-intensive, low throughput. | Truly homogeneous detection, "add-mix-incubate-read," no washing steps required, extremely simple operation, automation-friendly. |
| Detection Quality | Susceptible to interference from short-lived fluorescence in sample matrices, low signal-to-noise ratio. | Time-resolved detection, delayed measurement effectively subtracts background interference, delivering ultra-high signal-to-noise ratio and stable, reliable data. |
| Throughput and Cost | Difficult to perform large-scale compound screening. | Perfectly compatible with 384-well or 1536-well plates, optimized for high-throughput screening (HTS), significantly saving precious samples and reagent consumables. |
| Information Dimension | Typically only endpoint binding data. | Enables real-time kinetic monitoring, in-depth assessment of compound-induced binding rates and strength. |
III. Broad Application Scenarios
High-throughput screening of BCL6-targeting molecular glues/PROTACs: Rapidly discover novel active molecules capable of inducing CRBN-BCL6 binding from large compound libraries.
Structure-activity relationship (SAR) studies: Precisely quantify the impact of compound structural modifications on their induced binding efficacy (potency), efficiently guiding medicinal chemistry optimization.
Mechanism of action validation: Verify candidate compounds' ability to mediate specific ternary complex formation and clarify their mode of action.
Compound potency ranking: Provide quantitative binding activity data for different candidate molecules, enabling prioritization and subsequent development decisions.
IV. Summary
The Human BCL6/CRBN PROTAC Binding Kit transforms the complex detection of inducible protein-protein interactions into a simple, rapid, and high-quality homogeneous assay workflow. It is the ideal choice for tackling the BCL6 target and accelerating the discovery of next-generation protein degraders.
About This Product
Human BCL6/CRBN PROTAC Binding Kit (Product No.: UA086021) is developed and manufactured by UA-Bio. UA-Bio remains committed to providing high-performance, highly reliable innovative detection solutions for cutting-edge life science exploration and drug development. The launch of this kit demonstrates our technical capabilities in continuously delivering professional tools in advanced fields such as targeted protein degradation, empowering global research and industrial users to enhance R&D efficiency.
Contact UA-Bio for detailed technical information and ordering instructions.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 